Clinical Trials | October 27, 2021
Dr Lal PathLabs to acquire Suburban Diagnostics for Rs 925 crore
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
It has planned an investment of over Rs 80 crore in the next five years
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
These pouches, manufactured at UFlex India plant, will be exported to American markets and will be majorly used for packing edible products
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
Subscribe To Our Newsletter & Stay Updated
